Human immunodeficiency virus vaccine trials.
Cold Spring Harb Perspect Med., 2(12) (2012)
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.
Stat Commun Infect Dis., Oct;3(1) (2011)
MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.
PLoS ONE., 7(8):e43396 (2012)
Changes in the soluble mucosal immune environment during genital herpes outbreaks.
J. Acquir. Immune Defic. Syndr., Oct;61(2):194-202 (2012)
An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection.
J. Virol., Oct;86(19):10587-96 (2012)
A prospective cohort study of partner testing for herpes simplex virus and sexual behavior during pregnancy.
J. Infect. Dis., Aug;206(4):486-94 (2012)
Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Nov;18(11):1687-99 (2012)
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).
J. Infect. Dis., Jul;206(2):258-66 (2012)
Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
PLoS ONE., 7(4):e33969 (2012)
Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients.
Biol. Blood Marrow Transplant., Sep;18(9):1391-400 (2012)
Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa.
PLoS ONE., 6(10):e25571 (2011)
Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study).
J. Acquir. Immune Defic. Syndr., Jul;57(3):238-44 (2011)
Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.
J. Med. Virol., Oct;83(10):1696-703 (2011)
Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2.
Vaccine., Sep;29(40):7058-66 (2011)
The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions.
J. Infect. Dis., Aug;204(4):554-61 (2011)
Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.
PLoS ONE., 6(6):e20479 (2011)
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
Lancet Infect Dis., Jul;11(7):507-15 (2011)
Genital HSV detection among HIV-1-infected pregnant women in labor.
Infect Dis Obstet Gynecol., 2011:157680 (2011)
HIV-1 vaccines and adaptive trial designs.
Sci Transl Med., Apr;3(79):79ps13 (2011)
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.
J. Infect. Dis., May;203(10):1474-83 (2011)